International Journal For Multidisciplinary Research

E-ISSN: 2582-2160     Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 3 May-June 2024 Submit your research before last 3 days of June to publish your research paper in the issue of May-June.

The Review on Mucormycosis (Black Fungus)

Author(s) Dhiraj Sunil Bhamare, Rutuja S. Abhonkar
Country India
Abstract The presentation aims at overview of Mucormycosis, its basic introduction, sign & symptoms, present perspective of disease through the way of progressive research. Recent therapeutic advances have the potential to improve outcomes of mucormycosis. Lipid formulations of amphotericin B (LFAB) have evolved as the cornerstone of primary therapy for mucormycosis. Posaconazole may be useful as salvage therapy, but it cannot be recommended as primary therapy for mucormycosis on the basis of available data.A definitive trial is needed to confirm these results. Combination therapy with LFAB and the iron chelator, deferasirox, also improved outcomes in animal models of mucormycosis. Early initiation of therapy is critical to maximizing outcomes; recent developments in polymerase chain reaction technology are advancing early diagnostic strategies. Prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis. Also the presentation focuses on the treatment, the target area prevention and the precaution measures with respect to disease.
Keywords Mucormycosis, Blank Fungus
Field Medical / Pharmacy
Published In Volume 4, Issue 6, November-December 2022
Published On 2022-11-08
Cite This The Review on Mucormycosis (Black Fungus) - Dhiraj Sunil Bhamare, Rutuja S. Abhonkar - IJFMR Volume 4, Issue 6, November-December 2022. DOI 10.36948/ijfmr.2022.v04i06.973
DOI https://doi.org/10.36948/ijfmr.2022.v04i06.973
Short DOI https://doi.org/grb6ch

Share this